Abstract
Genetic changes involving the c-myc oncogene have been observed in human tumours. In particular, the c-myc gene is translocated in Burkitt's lymphoma1–3 and is amplified in the human promyelocytic leukaemia cell line. HL-60, which contains double minute chromosomes (DMs)4,5. More recently, an amplified c-myc gene has been positioned on a chromosomal homogeneous staining region (HSR) in a human colon cancer cell line, COLO 320, with neuroendocrine properties6. Furthermore, c-myc is expressed in increased amounts in some human tumour lines, and in some cases, human small cell lung cancers (SCLC) contain DMs and HSRs7,8. These findings prompted us to study the c-myc gene and its RNA expression in a series of human lung cancer cell lines. We now report amplification and expression of the c-myc oncogene in a system other than B-cell lymphomas9, namely human lung cancer. Of 18 human lung cancer cell lines tested, 8 showed an amplified 12.5-kilobase (kb) EcoRI c-myc DNA band. Of particular interest are five SCLC lines with a high degree of c-myc DNA amplification (20–76-fold) and greatly increased levels of c-myc RNA. All five lines reside in the variant class of SCLC (SCLC-V) characterized by altered morphology, lack of expression of some SCLC-dlfferentlated functions and more malignant behaviour than pure SCLC10,11. Three of the five lines which have been karyotyped also contain DMs or HSRs. The finding of a greatly amplified c-myc gene in all cell lines of the SCLC-V class examined strongly suggests a role for the c-myc gene in the phenotypic conversion and malignant behaviour of human lung cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Taub, R. et al. Proc. natn. Acad. Sci. U.S.A. 79, 7837–7841 (1982).
Dalla-Favera, R. et al. Science 219, 963–967 (1983).
Erikson, J. et al. Proc. natn. Acad. Sci. U.S.A. 80, 820–824 (1983).
Dalla-Favera, R., Wong-Staal, F. & Gallo, R. C. Nature 299, 61–63 (1982).
Collins, S. & Groudine, M. Nature 298, 679–681 (1982).
Alitalo, K. et al. Proc. natn. Acad. Sci. U.S.A. 80, 1707–1711 (1983).
Whang-Peng, J. et al. Cancer gen. Cytogenet. 6, 119–134 (1982).
Whang-Peng, J. et al. Science 215, 181–182 (1982).
Klein, G. Cell 32, 311–315 (1983).
Gazdar, A. F., Carney, D. N., Guccion, J. G. & Balyin, S. B. in Small Cell Carcinoma of the Lung (eds Greco, F. A., Oldham, R. K. & Bunn, P. A.) 145–175 (Grune & Stratton, New York, 1981).
Gazdar, A. F. et al. Cancer Res. 41, 2773–2777 (1981).
Abeloff, M. D. et al. Am. J. Med. 66, 757–762 (1979).
Matthews, M. J. in Lung Cancer: Progress in Therapeutic Research (eds Muggia, F. & Rozencweig, M.) 155–165 (Raven, New York, 1979).
Matthews, M. J. & Gazdar, A. F. in Lung Cancer I (ed. Livingston, R. B.) 283–306 (Martinus Nijhoff, Boston, 1981).
Baylin, S. B. et al. Cancer Res. 40, 1990–1996 (1980).
Moody, T. W. et al. Science 214, 1246–1248 (1981).
Marangos, P. J., Gazdar, A. F. & Carney, D. N. Cancer Lett. 15, 67–71 (1982).
Carney, D. N., Mitchell, J. B. & Kinsella, T. J. Cancer Res. 43, 2806–2811 (1983).
Radice, P. A. et al. Cancer 50, 2894–2902 (1982).
Gene Amplification. (ed. Schimke, R. T.) 1–339 (Cold Spring Harbor Laboratory, New York, 1982).
Curt, G. A. et al. New Engl. J. Med. 308, 199–202 (1983).
Whang-Peng, J. et al. in Gene Amplification (ed. Schimke, R. T.) 107–113 (Cold Spring Harbor Laboratory, New York, 1982).
Southern, E. J. molec. Biol. 98, 503–517 (1975).
Eva, A. et al. Nature 295, 116–119 (1982).
Neel, B. G., Jhanwar, S. C., Chaganti, R. S. K. & Hayward, W. S. Proc. natn. Acad. Sci. U.S.A. 79, 7842–7846 (1982).
Beaven, M. A., Wilcox, G. & Terpstra, G. K. Analytic. Biochem. 84, 648–641 (1978).
Gazdar, A. F. et al. Cancer Res. 40, 3502–3507 (1980).
Hieter, P. A. et al. Nature 294, 536–540 (1981).
Wahl, G. M., Stern, M. & Stark, G. R. Proc. natn. Acad. Sci. U.S.A. 76, 3683–3687 (1979).
Battey, J., Moulding, C., Taub, R. & Leder, P. Cell (submitted).
Fritisch, E. F., Lawn, R. M. & Maniatis, T. Cell 19, 959–972 (1980).
Gorman, C. M. et al. Proc. natn. Acad. Sci. U.S.A. 79, 677–6781 (1982).
Lehrach, H. et al. Biochemistry 16, 4743–4751 (1977).
Dalla-Favera, R. et al. Proc. natn. Acad. Sci. U.S.A. 79, 7824–7827 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Little, C., Nau, M., Carney, D. et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306, 194–196 (1983). https://doi.org/10.1038/306194a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/306194a0
This article is cited by
-
An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells
Cancer Cell International (2023)
-
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
Journal of Experimental & Clinical Cancer Research (2023)
-
Peptides as multifunctional players in cancer therapy
Experimental & Molecular Medicine (2023)
-
Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
Discover Oncology (2022)
-
Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts
Nature Communications (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.